Lexicon Pharmaceuticals (LXRX) Cash & Current Investments (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has reported Cash & Current Investments for 17 consecutive years, with $170.7 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash & Current Investments fell 12.41% year-over-year to $170.7 million; the TTM figure through Mar 2026 stood at $170.7 million (down 12.41% YoY), while the FY2025 annual figure was $96.2 million, down 59.56% from the prior year.
• Cash & Current Investments climbed to $170.7 million in Q1 2026 per LXRX's latest filing, from $96.2 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $355.6 million in Q1 2024 and bottomed at $62.0 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $179.6 million across 5 years, with a median of $170.0 million in 2023.
• Annual changes were most pronounced in 2023 — Cash & Current Investments soared 314.31% — and 2025, when it slumped 59.56%.
• Lexicon Pharmaceuticals' Cash & Current Investments stood at $138.4 million in 2022, then climbed by 22.89% to $170.0 million in 2023, then soared by 39.95% to $238.0 million in 2024, then plunged by 59.56% to $96.2 million in 2025, then surged by 77.34% to $170.7 million in 2026.
• Business Quant data shows LXRX's Cash & Current Investments at $170.7 million in Q1 2026, $96.2 million in Q4 2025, and $116.0 million in Q3 2025.